Reviewing Sutro Biopharma Inc. (STRO)’s and Aevi Genomic Medicine Inc. (NASDAQ:GNMX)’s results

This is a contrast between Sutro Biopharma Inc. (NASDAQ:STRO) and Aevi Genomic Medicine Inc. (NASDAQ:GNMX) based on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sutro Biopharma Inc. 11 5.11 N/A -1.66 0.00
Aevi Genomic Medicine Inc. N/A 0.00 N/A -0.43 0.00

Table 1 highlights Sutro Biopharma Inc. and Aevi Genomic Medicine Inc.’s gross revenue, earnings per share and valuation.


Table 2 demonstrates the return on assets, return on equity and net margins of Sutro Biopharma Inc. and Aevi Genomic Medicine Inc.

Net Margins Return on Equity Return on Assets
Sutro Biopharma Inc. 0.00% 0% 0%
Aevi Genomic Medicine Inc. 0.00% -264.5% -178.4%


The current Quick Ratio of Sutro Biopharma Inc. is 5.7 while its Current Ratio is 5.7. Meanwhile, Aevi Genomic Medicine Inc. has a Current Ratio of 1.9 while its Quick Ratio is 1.9. Sutro Biopharma Inc. is better positioned to pay off its short-term and long-term debts than Aevi Genomic Medicine Inc.

Insider and Institutional Ownership

The shares of both Sutro Biopharma Inc. and Aevi Genomic Medicine Inc. are owned by institutional investors at 73.1% and 6.4% respectively. Insiders owned roughly 21.23% of Sutro Biopharma Inc.’s shares. Competitively, 42.43% are Aevi Genomic Medicine Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sutro Biopharma Inc. 1.9% -4.09% 13.27% 5.52% 0% 24.94%
Aevi Genomic Medicine Inc. -9.48% -7.97% -32.82% -17.4% -83.14% -76.4%

For the past year Sutro Biopharma Inc. had bullish trend while Aevi Genomic Medicine Inc. had bearish trend.


Sutro Biopharma Inc. beats Aevi Genomic Medicine Inc. on 6 of the 7 factors.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.